Tarlatamab in Small Cell Lung Cancer and Extrapulmonary Small Cell Carcinoma: A Single-Centre Retrospective Cohort Study of Routine-Practice Outcomes
6 affiliations
- 1Department of Hematology and Oncology, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA
- 2Department of Bone Marrow Transplant and Cellular Therapy, Loma Linda University Health, Loma Linda, CA 92350, USA
- 3Division of Leukemia, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA
- 4Department of Internal Medicine, Hackensack Meridian Health, Palisades Medical Center, North Bergen, NJ 07047, USA
- 5Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
- 6Division of Thoracic and GI Oncology and Phase 1 Clinical Trial, Hackensack Meridian John Theurer Cancer Center, Hackensack, NJ 07047, USA
Abstract
Background: Tarlatamab, a Delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE), has demonstrated significant efficacy in relapsed small cell lung cancer (SCLC) in clinical trials. However, real-world clinical outcomes and its efficacy in extrapulmonary small cell carcinoma (EPSCC) remain sparsely characterized. Methods: We conducted a retrospective, single-institution cohort study of 24 adult patients with moderately pretreated advanced SCLC (n = 19) or EPSCC (n = 5) who received standard-of-care tarlatamab. Endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: Patients had received a median of two prior lines of therapy, and 38% had baseline brain metastases. The overall intent-to-treat (ITT) ORR was 25.0%. Among response-evaluable patients (n = 18), the ORR was 33.3%. Efficacy was notably discordant between histologies: the SCLC cohort achieved an ITT ORR of 31.6% (46.2% in evaluable patients), whereas 100% of EPSCC patients experienced progressive disease. Systemic responses were observed in patients with baseline brain metastases (ORR 33.3%). The safety profile was manageable; any-grade CRS and ICANS occurred in 58% and 29% of patients, respectively. Severe (Grade ≥ 3) toxicities were rare, and tocilizumab was utilized therapeutically in 50% of patients for low-grade toxicity. Conclusions: These real-world data are consistent with tarlatamab’s systemic efficacy and tolerability in SCLC. The lack of clinical benefit observed in this small EPSCC cohort raises a hypothesis that requires prospective biomarker-correlated evaluation.
Related
- Recorded Adverse Events and Patient-Reported Outcomes After Intra-articular Extracellular-Vesicle Product Administration for Knee Osteoarthritis: A Retrospective Single-Practice Case Series
- Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
- Survival outcomes of radiotherapy in elderly patients with unresectable stage III hepatocellular carcinoma: a population-based retrospective cohort study
- Hyaluronan-enriched transfer medium in routine clinical practice: a retrospective cohort study showing no improvement in pregnancy outcomes among predominantly frozen embryo transfer cycles
- Primary-site variation in recorded metastatic patterns and survival associations in extrapulmonary poorly differentiated neuroendocrine carcinoma
BibTeX
@article{bangolo2026tarlatamab,
title = {{Tarlatamab in Small Cell Lung Cancer and Extrapulmonary Small Cell Carcinoma: A Single-Centre Retrospective Cohort Study of Routine-Practice Outcomes}},
author = {Ayrton Bangolo and Lili Zhang and Jiahe Zhao and Behzad Amoozgar and Sarvarinder Gill and Shibhani Rajanna and Shareif Abdelwahab and Andres Molina and Tanner Robinson and Umangpreet Gill and Andrea Torres and Akhil Akula and Mahe Tahniyat and Maamoun Seklawi and Tri Vo and Thilini Suriyaarachchi and Oriana Castillo-Briceno and Sujeewa Kalubowila and Tori Salorenzo and Darya Klechykava and Avery Kellman and Kaushik Roy and Victor H. Villarreal and Alia Ramzan and Hamza Haq and Rajendra Gunti and Soroush Abaresh and Gurmanjot Kaur and Jonathan Montalvo and Zhongxuan-Jonathan Wang and Aanya Srivastava and Lipi Gudiboina and Benjamin S. Feuer and Vennela Talla and Rajin Persaud and Winnie Noe and Shalini Subramanian and Simcha Weissman and Martin Gutierrez and Miguel Gonzalez-Velez},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193078},
url = {https://europepmc.org/article/PMC/PMC13663987},
note = {CC BY},
}
RIS
TY - JOUR
TI - Tarlatamab in Small Cell Lung Cancer and Extrapulmonary Small Cell Carcinoma: A Single-Centre Retrospective Cohort Study of Routine-Practice Outcomes
AU - Ayrton Bangolo
AU - Lili Zhang
AU - Jiahe Zhao
AU - Behzad Amoozgar
AU - Sarvarinder Gill
AU - Shibhani Rajanna
AU - Shareif Abdelwahab
AU - Andres Molina
AU - Tanner Robinson
AU - Umangpreet Gill
AU - Andrea Torres
AU - Akhil Akula
AU - Mahe Tahniyat
AU - Maamoun Seklawi
AU - Tri Vo
AU - Thilini Suriyaarachchi
AU - Oriana Castillo-Briceno
AU - Sujeewa Kalubowila
AU - Tori Salorenzo
AU - Darya Klechykava
AU - Avery Kellman
AU - Kaushik Roy
AU - Victor H. Villarreal
AU - Alia Ramzan
AU - Hamza Haq
AU - Rajendra Gunti
AU - Soroush Abaresh
AU - Gurmanjot Kaur
AU - Jonathan Montalvo
AU - Zhongxuan-Jonathan Wang
AU - Aanya Srivastava
AU - Lipi Gudiboina
AU - Benjamin S. Feuer
AU - Vennela Talla
AU - Rajin Persaud
AU - Winnie Noe
AU - Shalini Subramanian
AU - Simcha Weissman
AU - Martin Gutierrez
AU - Miguel Gonzalez-Velez
PY - 2026
DA - 2026/09/22
JO - Cancers
DO - 10.3390/cancers18193078
UR - https://europepmc.org/article/PMC/PMC13663987
AB - Background: Tarlatamab, a Delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE), has demonstrated significant efficacy in relapsed small cell lung cancer (SCLC) in clinical trials. However, real-world clinical outcomes and its efficacy in extrapulmonary small cell carcinoma (EPSCC) remain sparsely characterized. Methods: We conducted a retrospective, single-institution cohort study of 24 adult patients with moderately pretreated advanced SCLC (n = 19) or EPSCC (n = 5) who received standard-of-care tarlatamab. Endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: Patients had received a median of two prior lines of therapy, and 38% had baseline brain metastases. The overall intent-to-treat (ITT) ORR was 25.0%. Among response-evaluable patients (n = 18), the ORR was 33.3%. Efficacy was notably discordant between histologies: the SCLC cohort achieved an ITT ORR of 31.6% (46.2% in evaluable patients), whereas 100% of EPSCC patients experienced progressive disease. Systemic responses were observed in patients with baseline brain metastases (ORR 33.3%). The safety profile was manageable; any-grade CRS and ICANS occurred in 58% and 29% of patients, respectively. Severe (Grade ≥ 3) toxicities were rare, and tocilizumab was utilized therapeutically in 50% of patients for low-grade toxicity. Conclusions: These real-world data are consistent with tarlatamab’s systemic efficacy and tolerability in SCLC. The lack of clinical benefit observed in this small EPSCC cohort raises a hypothesis that requires prospective biomarker-correlated evaluation.
SN - 2072-6694
ER -